Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility is currently unavailable.

Tracy Todd Batchelor, M.D.

Co-Author

This page shows the publications co-authored by Tracy Batchelor and Jorg Dietrich.
Connection Strength

5.210
  1. Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial. Oncologist. 2020 09; 25(9):747-e1273.
    View in: PubMed
    Score: 0.942
  2. Intracranial Foreign Body Granuloma Mimicking Brain Tumor Recurrence: A Case Series. Oncologist. 2021 Mar 29.
    View in: PubMed
    Score: 0.248
  3. Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa157.
    View in: PubMed
    Score: 0.242
  4. Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma. JCO Precis Oncol. 2020; 4.
    View in: PubMed
    Score: 0.235
  5. Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. Clin Cancer Res. 2020 01 01; 26(1):206-212.
    View in: PubMed
    Score: 0.223
  6. Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology. Neuro Oncol. 2019 09 06; 21(9):1118-1130.
    View in: PubMed
    Score: 0.223
  7. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019 05 16; 133(20):2212-2221.
    View in: PubMed
    Score: 0.215
  8. MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. Blood Adv. 2019 02 12; 3(3):375-383.
    View in: PubMed
    Score: 0.214
  9. Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic Study. Oncologist. 2019 03; 24(3):402-413.
    View in: PubMed
    Score: 0.207
  10. Bone marrow drives central nervous system regeneration after radiation injury. J Clin Invest. 2018 06 01; 128(6):2651.
    View in: PubMed
    Score: 0.204
  11. Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. Nat Commun. 2018 04 16; 9(1):1474.
    View in: PubMed
    Score: 0.202
  12. Standard chemoradiation in combination with VEGF targeted therapy for glioblastoma results in progressive gray and white matter volume loss. Neuro Oncol. 2018 01 22; 20(2):289-291.
    View in: PubMed
    Score: 0.199
  13. Bone marrow drives central nervous system regeneration after radiation injury. J Clin Invest. 2018 01 02; 128(1):281-293.
    View in: PubMed
    Score: 0.197
  14. Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. NPJ Precis Oncol. 2017; 1.
    View in: PubMed
    Score: 0.191
  15. Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case series. Neurooncol Pract. 2018 Mar; 5(1):64-68.
    View in: PubMed
    Score: 0.190
  16. Standard chemoradiation for glioblastoma results in progressive brain volume loss. Neurology. 2015 Aug 25; 85(8):683-91.
    View in: PubMed
    Score: 0.167
  17. Increased perfusion due to vascular normalization improves oxygenation and survival in glioblastoma patients treated with cediranib with or without chemoradiation. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii12.
    View in: PubMed
    Score: 0.155
  18. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):19059-64.
    View in: PubMed
    Score: 0.149
  19. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol. 2013 Jan; 10(1):14-26.
    View in: PubMed
    Score: 0.139
  20. A Rapid Genotyping Panel for Detection of Primary Central Nervous System Lymphoma. Blood. 2021 Mar 18.
    View in: PubMed
    Score: 0.062
  21. An integrated RF-receive/B0-shim array coil boosts performance of whole-brain MR spectroscopic imaging at 7 T. Sci Rep. 2020 09 14; 10(1):15029.
    View in: PubMed
    Score: 0.060
  22. Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020 Aug; 26(8):1309.
    View in: PubMed
    Score: 0.059
  23. Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020 08; 26(8):1280-1284.
    View in: PubMed
    Score: 0.059
  24. Perceptions of prognosis and goal of treatment in patients with malignant gliomas and their caregivers. Neurooncol Pract. 2020 Oct; 7(5):490-497.
    View in: PubMed
    Score: 0.058
  25. Primary dural lymphomas: Clinical presentation, management, and outcome. Cancer. 2020 06 15; 126(12):2811-2820.
    View in: PubMed
    Score: 0.058
  26. Super-Resolution Whole-Brain 3D MR Spectroscopic Imaging for Mapping D-2-Hydroxyglutarate and Tumor Metabolism in Isocitrate Dehydrogenase 1-mutated Human Gliomas. Radiology. 2020 03; 294(3):589-597.
    View in: PubMed
    Score: 0.057
  27. Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide. J Neurooncol. 2019 Mar; 142(1):69-77.
    View in: PubMed
    Score: 0.053
  28. Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. J Neurooncol. 2017 02; 131(3):603-610.
    View in: PubMed
    Score: 0.046
  29. Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. Clin Cancer Res. 2016 Apr 01; 22(7):1632-41.
    View in: PubMed
    Score: 0.043
  30. Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. J Neurooncol. 2015 Feb; 121(3):557-63.
    View in: PubMed
    Score: 0.040
  31. Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer. 2015 Jan 15; 121(2):226-33.
    View in: PubMed
    Score: 0.039
  32. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro Oncol. 2013 Aug; 15(8):1079-87.
    View in: PubMed
    Score: 0.036
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.